Takamatsu J, Hosoya T, Naito N, Yoshimura H, Kohno Y, Tarutani O, Kuma K, Sakane S, Takeda K, Mozai T
Department of Medicine, Osaka Medical College, Japan.
J Clin Endocrinol Metab. 1988 Jan;66(1):147-52. doi: 10.1210/jcem-66-1-147.
Some patients with hyperthyroid Graves' disease have increased serum T3 and normal or even low serum T4 levels during treatment with antithyroid drugs. These patients with elevated serum T3 to T4 ratios rarely have a remission of their hyperthyroidism. The aim of this study was to investigate thyroid iodine metabolism in such patients, whom we termed T3-predominant Graves' disease. Mean thyroid radioactive iodine uptake was 51.0 +/- 18.1% ( +/- SD) at 3 h, and it decreased to 38.9 +/- 20.1% at 24 h in 31 patients with T3-predominant Graves' disease during treatment. It was 20.0 +/- 11.4% at 3 h and increased to 31.9 +/- 16.0% at 24 h in 17 other patients with hyperthyroid Graves' disease who had normal serum T3 and T4 levels and a normal serum T3 to T4 ratio during treatment (control Graves' disease). The activity of serum TSH receptor antibodies was significantly higher in the patients with T3-predominant Graves' disease than in control Graves' disease patients (60.5 +/- 19.2% vs. 20.4 +/- 18.2%; P less than 0.001). From in vitro studies of thyroid tissue obtained at surgery, both thyroglobulin content and iodine content in thyroglobulin were significantly lower in patients with T3-predominant Graves' disease than in the control Graves' disease patients. Thyroid peroxidase (TPO) activity determined by a guaiacol assay was 0.411 +/- 0.212 g.u./mg protein in the T3-predominant Graves' disease patients, significantly higher than that in the control Graves' disease patients (0.129 +/- 0.112 g.u./mg protein; P less than 0.01). Serum TPO autoantibody levels determined by immunoprecipitation also were greater in T3-predominant Graves' disease patients than in control Graves' disease patients (52.6 +/- 27.7% vs. 32.4 +/- 11.4%; P less than 0.05). Binding of this antibody to TPO slightly inhibited the enzyme activity of TPO, but this effect of the antibody was similar in the two groups of patients. The data suggest enhanced iodine metabolism in the thyroid gland of patients with T3-predominant Graves' disease, which may relate to the discordant T3 overproduction in patients with this type of Graves' disease.
一些患有甲状腺功能亢进型格雷夫斯病的患者在使用抗甲状腺药物治疗期间,血清T3升高而血清T4水平正常甚至降低。这些血清T3与T4比值升高的患者很少能缓解甲状腺功能亢进。本研究的目的是调查这类患者的甲状腺碘代谢,我们将这类患者称为T3为主型格雷夫斯病。31例T3为主型格雷夫斯病患者在治疗期间,甲状腺放射性碘摄取率在3小时时平均为51.0±18.1%(±标准差),24小时时降至38.9±20.1%。17例其他甲状腺功能亢进型格雷夫斯病患者在治疗期间血清T3和T4水平正常且血清T3与T4比值正常(对照格雷夫斯病),其甲状腺放射性碘摄取率在3小时时为20.0±11.4%,24小时时升至31.9±16.0%。T3为主型格雷夫斯病患者血清促甲状腺激素受体抗体活性显著高于对照格雷夫斯病患者(60.5±19.2%对20.4±18.2%;P<0.001)。通过对手术获取的甲状腺组织进行体外研究发现,T3为主型格雷夫斯病患者的甲状腺球蛋白含量和甲状腺球蛋白中的碘含量均显著低于对照格雷夫斯病患者。通过愈创木酚法测定的甲状腺过氧化物酶(TPO)活性在T3为主型格雷夫斯病患者中为0.411±0.212酶单位/毫克蛋白,显著高于对照格雷夫斯病患者(0.129±0.112酶单位/毫克蛋白;P<0.01)。通过免疫沉淀法测定的血清TPO自身抗体水平在T3为主型格雷夫斯病患者中也高于对照格雷夫斯病患者(52.6±27.7%对32.4±11.4%;P<0.05)。该抗体与TPO的结合对TPO的酶活性有轻微抑制作用,但两组患者中该抗体的这种作用相似。数据表明T3为主型格雷夫斯病患者甲状腺中的碘代谢增强,这可能与这类格雷夫斯病患者T3过度产生不一致有关。